| Bioactivity | Refanezumab (GSK249320) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier (BBB) in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke[1][2]. |
| In Vivo | Refanezumab (GSK249320; 10 mg/kg; 静脉给药; 在中风后 24 小时开始并每周继续给药 6 次) 显示神经评分和阶梯测试有更大的增加。Refanezumab 通过静脉注射后，可穿透病变部位，并且在中风后 24 小时对功能结果有轻微影响。 Animal Model: |
| Name | Refanezumab |
| CAS | 1233953-61-1 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Diana Cash, et al. GSK249320, A Monoclonal Antibody Against the Axon Outgrowth Inhibition Molecule Myelin-Associated Glycoprotein, Improves Outcome of Rodents with Experimental Stroke. J Neurol Exp Neurosci. 2016;2(2):28-33. Epub 2016 Nov 21. [2]. B Abila, et al. First-time-in-human study with GSK249320, a myelin-associated glycoprotein inhibitor, in healthy volunteers. Clin Pharmacol Ther. 2013 Feb;93(2):163-9. |